Comprehensive Review on Recent Strategies for Management of Prostate Cancer : Therapeutic Targets and SAR
Copyright© Bentham Science Publishers; For any queries, please email at epubbenthamscience.net..
Prostate cancer is a disease that is affecting a large population worldwide. Androgen deprivation therapy (ADT) has become a foundation for the treatment of advanced prostate cancer, as used in most clinical settings from neo-adjuvant to metastatic stage. In spite of the success of ADT in managing the disease in the majority of men, hormonal manipulation fails eventually. New molecules are developed for patients with various hormone-refractory diseases. Advancements in molecular oncology have increased understanding of numerous cellular mechanisms which control cell death in the prostate and these insights can lead to the development of more efficacious and tolerable therapies for carcinoma of the prostate. This review is focused on numerous therapies that might be a boon for prostate therapy like signaling inhibitors, vaccines, and inhibitors of androgen receptors. Along with these, various bioactive molecules and their derivatives are highlighted, which act as potential anti-prostate cancer agents. This article also emphasized the recent advances in the field of medicinal chemistry of prostate cancer agents.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - year:2023 |
|---|---|
| Enthalten in: |
Mini reviews in medicinal chemistry - (2023) vom: 11. Sept. |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Chaudhary, Manish [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Arylpiperazine |
|---|
| Anmerkungen: |
Date Revised 11.09.2023 published: Print-Electronic Citation Status Publisher |
|---|
| doi: |
10.2174/1389557523666230911141339 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM361922280 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM361922280 | ||
| 003 | DE-627 | ||
| 005 | 20231226090152.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.2174/1389557523666230911141339 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1206.xml |
| 035 | |a (DE-627)NLM361922280 | ||
| 035 | |a (NLM)37694781 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Chaudhary, Manish |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Comprehensive Review on Recent Strategies for Management of Prostate Cancer |b Therapeutic Targets and SAR |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 11.09.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status Publisher | ||
| 520 | |a Copyright© Bentham Science Publishers; For any queries, please email at epubbenthamscience.net. | ||
| 520 | |a Prostate cancer is a disease that is affecting a large population worldwide. Androgen deprivation therapy (ADT) has become a foundation for the treatment of advanced prostate cancer, as used in most clinical settings from neo-adjuvant to metastatic stage. In spite of the success of ADT in managing the disease in the majority of men, hormonal manipulation fails eventually. New molecules are developed for patients with various hormone-refractory diseases. Advancements in molecular oncology have increased understanding of numerous cellular mechanisms which control cell death in the prostate and these insights can lead to the development of more efficacious and tolerable therapies for carcinoma of the prostate. This review is focused on numerous therapies that might be a boon for prostate therapy like signaling inhibitors, vaccines, and inhibitors of androgen receptors. Along with these, various bioactive molecules and their derivatives are highlighted, which act as potential anti-prostate cancer agents. This article also emphasized the recent advances in the field of medicinal chemistry of prostate cancer agents | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Arylpiperazine | |
| 650 | 4 | |a Bicalutamide | |
| 650 | 4 | |a Flavonoids | |
| 650 | 4 | |a Prostate Cancer | |
| 650 | 4 | |a Recent Advances | |
| 650 | 4 | |a Therapeutic Targets | |
| 700 | 1 | |a Kumar, Shubham |e verfasserin |4 aut | |
| 700 | 1 | |a Kaur, Paranjeet |e verfasserin |4 aut | |
| 700 | 1 | |a Sahu, Sanjeev Kumar |e verfasserin |4 aut | |
| 700 | 1 | |a Mittal, Amit |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Mini reviews in medicinal chemistry |d 2001 |g (2023) vom: 11. Sept. |w (DE-627)NLM121595404 |x 1875-5607 |7 nnns |
| 773 | 1 | 8 | |g year:2023 |g day:11 |g month:09 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.2174/1389557523666230911141339 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |j 2023 |b 11 |c 09 | ||